Back to Results
Evaluating Cosentyx for Patients With Hidradenitis Suppurativa
||Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa
||David Rosmarin, MD
The purpose of this study is to find out more about a drug call subcutaneous (injectable) secukinumab in people iwth hidranetis suppurativa. Secukinumab may be successful in treating hidranetis suppurativa because it is an injectable drug known as a "biologic" that blocks a specific molecule of the immune system called interleukin-7A. This molecule is increased in people with hidranetis suppurativa. By blocking interleukin-17A, we believe that secukinumab will help treat the lesions of hidranetis suppurativa.
- Subjects has moderate-to-sever HS as defined by:
- HS lesions in a least 2 distinct anatomic areas, one of which is Hurley stage II or III on evaluation at Screening
- Stable HS for at least 2 months (60 days) prior to Screener and also at the Baseline visit as determined by the investigator.
- Total abscess and inflammatory nodule (AN) count of great than or equal to 3 at the Baseline visit
- Subject has had HS diagnosis for at least 3 months prior to Baseline visit
- Subjects must have failed at least one prior course of oral antibiotics.
- Subject has previously used secukinumab
- Subject has had any other active skin disease or condition that may interfere with HS assessment.
- Women who are pregnant, nursing, or planning pregnancy with 6 months after last subcutaneous injection. Male patients who are planning for their partner's pregnancies within 6 months from the last subcutaneous injection.
16 visits over approximately 8 months time. Labs are collected at every visit with the total amount of blood being collected at each visit being approximately 1-2 teaspoons.